


Goldstein, Jeffrey M

From: Goldstein, Jeffrey M
Sent: Friday, February 23, 2001 10:31 AM
To: 'ajg@liverpool.ac.uk'
Subject: FW: Quetiapine Matters



Andrew,

I have finally heard back from my colleagues in the UK. Unfortunately, they have declined interest in the study for reasons that are similar to what I mentioned below: we already have a strong weight message based on clinical data, and there is a risk that preclinical findings may not work out in our favor and therefore weaken our message. This is not a risk the commercial folks want to take. Sorry I didn't have better news.

I have not heard back about funding your trip, so as soon as I do I'll let you know.

Regards,

Jeff

-----Original Message-----

From: Goldstein, Jeffrey M
Sent: Tuesday, February 20, 2001 11:15 AM
To: 'Andrew Goudie'
Subject: RE: Quetiapine Matters

Hi Andrew,

I will check to see if we can fund your travel to this meeting. Budgets are very tight so I can't promise anything, but I will try.

Your observations about the importance of the weight issues are right on target. However, in the new world of AstraZeneca, priorities are constantly shifting and even though this is of scientific interest, you need to see it from the non-scientist commercial point of view - we already have clinical findings which clearly differentiate Seroquel from the others, so why go back to preclinical? At the best the studies would only confirm our clinical findings, at the worst we could wind up with results that are not clearly advantageous to Seroquel and perhaps muddy the waters.

That said, I am still trying to get the commercial folks to buy into doing the work. All I can say is to stay in contact, and as soon as I hear anything definitive, I'll certainly let you know.

I'll get back to you on the funding as soon as I have an answer.

Kindest regards,

Jeff

-----Original Message-----

From: Andrew Goudie [mailto:ajg@liverpool.ac.uk]
Sent: Tuesday, February 20, 2001 6:55 AM
To: Goldstein, Jeffrey M
Cc: ajg@liverpool.ac.uk
Subject: RE: Quetiapine Matters

Dear Jeff,

I have two requests for you:-

1) Is there any chance that AstraZeneca would sponsor me to attend the British Association of Psychopharmacology Meeting in July to present out data on quetiapine drug discrimination. This would essentially be the same data we presented at CINP, with a few extra drugs added in. The total cost would be around £ 450. The meeting is attended by a considerable number of UK Psychiatrists.

ii) I have just come across an AstraZeneca press release on the WWW from ACNP in December to the effect that quetiapine does not induce weight gain in humans. Given that we have data already showing that one novel antipsychotic induces weight gain in rats, a COMPARATIVE negative finding with quetiapine in rats would surely be of great interest to you. Hence I am a little puzzled that you indicated that our application for experimental support was "bogged down". Is there anything I can do to get this work funded, it does seem very important to me.

Sorry to appear to "hassle" you. I hope all goes well.

Andrew Goudie.

> On Thu, 8 Feb 2001 10:05:23 -0500 "Goldstein, Jeffrey M"
> <jeffrey.goldstein@astrazeneca.com> wrote:
>
> > Hi Andrew,
> >
> > I have tried to get the company interested in doing this work, but it has
> > been discussed several times and appears to now be thrown back into the
> > hands of the local marketing company in UK. I am very frustrated at the way
> > this was all handled and it is not fair to keep you on hold for such a long
> > time. Although I still do not have an answer for you, it is more then likely
> > this will be further debated to the point of diminishing returns. I can only
> > offer my apologies at the way this was handled and say that at this point in
> > time, it is more unlikely then likely this will be funded.
> >
> > If I hear of anything that sounds more encouraging, I'll get back to you. I
> > am sorry I could not offer you more hope at this time.
> >
> > Regards,
> >
> > Jeff

> >
> > -----Original Message-----
> > From: Andrew Goudie [mailto:ajg@liverpool.ac.uk]
> > Sent: Thursday, February 08, 2001 9:38 AM
> > To: Goldstein, Jeffrey M
> > Subject: Request for information
> >
> >
> > Dear Jeff,
> >
> > Hope all is well. Do you have any information on
> >
> > the progress (or lack of it) on our weight gain proposal?
> >
> > Best wishes,
> >
> >
> > Andrew Goudie.
> > -----
> > ajg@liverpool.ac.uk
> >
> > Dr Andrew Goudie,
> > Reader in Psychopharmacology,
> > Psychology Dept,
> > Liverpool University,
> > Eleanor Rathbone Building,
> > Bedford Street,
> > Liverpool,
> > L69 7ZA, U.K.

> >
> > Tel: U.K. 0151 - 794 - 2951 (2956/7 for messages)
> > Fax: U.K. 0151 - 794 - 2945
> >
> >
> >
> >
> >
> >
> >
> >

> > -----
> > ajg@liverpool.ac.uk
> >
> > Dr Andrew Goudie,
> > Reader in Psychopharmacology,
> > Psychology Dept,
> > Liverpool University,
> > Eleanor Rathbone Building,
> > Bedford Street,
> > Liverpool,
> > L69 7ZA, U.K.

> >
> > Tel: U.K. 0151 - 794 - 2951 (2956/7 for messages)
> > Fax: U.K. 0151 - 794 - 2945
> >
> >
> >
> >
> >
> >

ajg@liverpool.ac.uk

Dr Andrew Goudie,
Reader in Psychopharmacology,
Psychology Dept,

Liverpool University,
Eleanor Rathbone Building,
Bedford Street,
Liverpool,
L69 7ZA, U.K.

Tel: U.K. 0151 - 794 - 2951 (2956/7 for messages)
Fax: U.K. 0151 - 794 - 2945